share_log

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech宣佈200萬美元的註冊直接發行定價
AIM ImmunoTech ·  05/31 00:00

OCALA, Fla., May 31, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregistered Class B warrants to purchase up to an aggregate of 5,640,958 shares of common stock. The Class A and Class B warrants will each have an exercise price of $0.363, will be exercisable six months from the date of issuance and, in the case of the Class A warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class B warrants, will expire on the five-year anniversary from the initial exercise date.

aim immunotech今天宣佈,與一家機構投資者簽訂證券購買協議,以每股0.363美元的價格購買5640958股已註冊的直接發售普通股。同時,公司還同意向單個投資者發行不記名的A類和B類認股證,其總認購量爲5640958股。A類和B類認股證的行權價格均爲0.363美元,並將在發行日期6個月後行權,在A類認股證的情況下,有效期爲初始行權日期的18個月週年紀念日,在B類認股證的情況下,有效期爲初始行權日期的5年週年紀念日。

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.0 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.

在扣除發售代理商費用和公司支付的其他預計發行費用之前,這次已註冊的直接發售和同時進行的定向增發,公司的總收益預計約爲200萬美元。

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Maxim Group LLC是本次發售的唯一承銷商。

The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 4, 2022. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, at (212) 895-3745.

普通股的發行是根據S-3表格(文件編號333-262280)的擱置登記聲明進行的,該表格於2022年2月4日被美國證券交易委員會(“SEC”)宣佈生效。發行普通股僅通過構成有效登記聲明一部分的招股說明書和招股說明書補充信息的方式進行。公司將向SEC提交有關該等普通股的招股說明書補充信息。招募說明書補充文件有關的,與附隨的招募說明書一起,可在SEC網站www.sec.gov或位於紐約市公園大道300號的Maxim Group LLC(電話:212-895-3745)上獲得。

The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, the warrants and the shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

定向增發的認股證和行使該等認股證而發行的普通股是根據1933年修訂版證券法(“證券法”)第4(a)(2)條和制定在該條例規下的D條例的私人發售而發行的,並且未在證券法或適用的州證券法下進行註冊。因此,除非符合證券法和適用州證券法的註冊要求或適用例外規定,否則該等認股證和認股證下的普通股不得在美國境內或通過郵遞物品或在美國以外的任何其他方式進行出售。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

此新聞稿不構成任何證券的銷售要約或要約,也不在任何州或其他司法轄區進行出售是違法的,在任何此類州或其他司法轄區之前,該等證券的註冊或符合註冊條件或適用證券法在該等州或其他司法轄區的要求。

About AIM ImmunoTech Inc.

AIM Immunotech股份有限公司是一家免疫藥品公司,專注於研究和開發治療多種癌症、免疫性疾病和病毒性疾病(包括COVID-19)的治療藥物。該公司的主要產品是一種名爲Ampligen(吡咯烷寡核苷酸)的首創調節免疫器官的藥物,具有廣泛的臨床試驗、覆蓋全球重要癌症、病毒性疾病和免疫系統疾病的廣譜活性。

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

AIM Immunotech公司是一家免疫藥物公司,專注於研究和開發治療多種癌症、免疫失調和病毒性疾病(包括COVID-19)的治療藥物。該公司的主要產品是一種名爲Ampligen(Rintatolimod)的首創性調節免疫藥物,是一種dsRNA和高選擇性TLR3激動劑,廣泛應用於針對全球重要癌症、病毒性疾病和免疫系統疾病的臨床試驗中。

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

欲了解更多信息,請訪問aimimmuno.com,並加入公司的X、LinkedIn和Facebook。

Cautionary Statement

聲明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan," "anticipate," "continue," "believe," "potential," "upcoming" and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

本新聞稿包含根據1995年《私人證券訴訟改革法》(“PSLRA”)的前瞻性陳述。諸如“可能”、“將”、“期望”、“計劃”、“預計”、“繼續”、“相信”、“潛在”、“即將”和其他類似表達的詞語變化及其變種(以及參照未來事件或情況的其他詞語或表達方式)旨在識別前瞻性陳述。許多這些前瞻性陳述涉及多項風險和不確定性。公司敦促投資者特別考慮其最新的10-K表格中標識的各種風險因素,以及在任何隨後提交的10-Q表格或8-K表格中包括的任何風險因素或警示性聲明,這些表格已提交給美國證券交易委員會。您被警告不要過度依賴這些前瞻性陳述,這些陳述僅於本新聞稿發表日期。就這些聲明而言,公司聲稱獲得PSLRA中對前瞻性陳述的安全港保護。公司不承諾更新任何這些前瞻性陳述以反映此後發生的事件或情況。

Investor Contact:

投資者聯繫人:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com

JTC Team,LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com

Primary Logo

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論